NASDAQ:TVGN Tevogen Bio Q2 2026 Earnings Results & Report $5.69 -0.53 (-8.52%) Closing price 11/17/2026 03:53 PM EasternExtended Trading$5.74 +0.04 (+0.79%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tevogen Bio beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$1.52 versus the -$2.53 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market Opens Tevogen Bio EPS ResultsActual EPS-$1.52Consensus EPS -$2.53Beat/MissBeat by +$1.01One Year Ago EPSN/AEPS Beat Rate5 of last 5 quartersTevogen Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Tevogen Bio Q2 2026 Earnings FAQ Did Tevogen Bio beat earnings estimates for Q2 2026? Tevogen Bio (NASDAQ:TVGN) reported earnings of -$1.52 per share for Q2 2026, beating the consensus estimate of -$2.53. The report was announced on Friday, August 14, 2026. Tevogen Bio Earnings HeadlinesTevogen Complements Capital Access with Two-Year Extension to Loan AgreementNovember 9, 2026 | globenewswire.comTevogen Regains Compliance with Nasdaq Global Market Continued Listing RequirementsSeptember 30, 2026 | globenewswire.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 18 at 1:00 AM | Porter & Company (Ad)Tevogen Bio Holdings Rebrands as Tevogen Inc.July 30, 2026 | tipranks.comTevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGNJuly 24, 2026 | benzinga.comTevogen Bio Announces 2026 Annual Meeting of StockholdersJuly 13, 2026 | globenewswire.comSee More Tevogen Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email. Email Address About Tevogen BioTevogen Bio (NASDAQ:TVGN) is a clinical-stage biotechnology company developing cell-based immunotherapies. Its ExacTcell platform uses donor-derived, antigen-specific T cells designed to recognize and attack disease-associated targets, with the goal of making therapies available without creating a custom treatment for each patient. The company’s lead investigational candidate, TVGN 489, is a T-cell therapy being developed for COVID-19. Tevogen is also pursuing potential applications of its platform in cancer and other diseases. Its candidates remain investigational and are not approved treatments. Founded by physician and health economist Ryan Saadi, who serves as the company’s chief executive officer, Tevogen became a publicly traded company in 2024 through a merger with Semper Paratus Acquisition Corporation. The company is based in Warren, New Jersey.View Tevogen Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.